VISN Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$17.33median target· current $11.74 (+47.6%)4 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
13 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio17.26Forward 3.72
EPS (TTM)$0.68704.0% YoY
Profit margin347.7%TECHNOLOGY
Market cap$2.65BMid cap
Valuation
- Forward P/E
- 3.72
- PEG ratio
- 2.94
- P/B
- 0.58
- P/S (TTM)
- 1.31
- EV/EBITDA
- 0.49
Profitability & growth
- ROE (TTM)
- 13.1%
- Operating margin
- 7.1%
- Revenue growth YoY
- 21.6%
- Dividend yield
- 0.0%
- Beta
- 1.93
Last earnings
Apr 30, 2026 · Estimate $0.22 · Reported $0.34
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About CommScope Holding Company, Inc.
Company profileGyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.
Classification
- Sector
- Technology
- Industry
- Communication Equipment
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 2601 TELECOM PARKWAY, RICHARDSON, TX
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$2.65B
Shares outstanding$225.6M
52W high$13.22
52W low$6.29
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent